Characterization of blood monocyte phenotype in patients with endometrial cancer

International Journal of Gynecological Cancer

Volumn 22, Issue 9, 2012, Pages 1500-1508

  Brooks, Nicole ^a,b   Stojanovska, Lily ^c   Grant, Peter ^d   Apostolopoulos, Vasso ^b   McDonald, Christine F ^e   Pouniotis, Dodie S ^a,e  

^a RMIT UNIVERSITY   (Australia)

^b Burnet Institute   (United States)

^c UNIVERSITY OF VICTORIA   (Canada)

^d MERCY HOSPITAL FOR WOMEN   (Australia)

^e AUSTIN HEALTH   (Australia)

Author keywords

Blood monocytes; Cytokines; Endometrial cancer; Phenotype

Indexed keywords

CD14 ANTIGEN; VASCULOTROPIN RECEPTOR 1;

ARTICLE; CANCER PATIENT; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; ENDOMETRIUM CANCER; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; MONOCYTE; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

AGED; CARCINOMA, ENDOMETRIOID; CASE-CONTROL STUDIES; CELL ADHESION; CYTOKINES; ENDOMETRIAL NEOPLASMS; FEMALE; FLOW CYTOMETRY; HUMANS; MIDDLE AGED; MONOCYTES; NEOVASCULARIZATION, PATHOLOGIC; PHAGOCYTOSIS; PHENOTYPE;

EID: 84872319447     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1097/IGC.0b013e3182249273     Document Type: Article

References (20)

1. Prat J, Gallardo A, Cuatrecasas M, et al. Endometrial carcinoma: pathology and genetics. Pathology. 2007;39:72-87.
2. Ryan AJ, Susil B, Jobling TW, et al. Endometrial cancer. Cell Tissue Res. 2005;322:53-61.
3. Robertson G. Screening for endometrial cancer. Med J Aust. 2005;178:657-659.
4. Santin AD, Bellone S, Van Stedum S, et al. Amplification of c-erbB2 oncogene: a major prognostic indicator in uterine serous papillary carcinoma. Cancer. 2005;104: 1391-1397.
5. Santin AD, Bellone S, Ravaggi A, et al. Induction of tumour-specific CD8(+) cytotoxic T lymphocytes by tumour lysate-pulsed autologous dendritic cells in patients with uterine serous papillary cancer. Br J Cancer. 2002;86: 151-157.
6. Santin AD, Bellone S, Van Stedum S, et al. Determination of HER2/neu status in uterine serous papillary carcinoma: comparative analysis of immunohistochemistry and fluorescence in situ hybridization. Gynecol Oncol. 2005;98:24-30.
7. Oehler MK, Fung A, Jobling TW. Advances in the treatment of endometrial cancer. J Br Menopause Soc. 2005;11: 18-22.
8. Amant F, Moerman P, Neven P, et al. Endometrial cancer. Lancet. 2005;366:491-505.
9. Santin AD, Hermonat PL, Ravaggi A, et al. Development and therapeutic effect of adoptively transferred T cells primed by tumor lysate-pulsed autologous dendritic cells in a patient with metastatic endometrial cancer. Gynecol Obstet Invest. 2000;49:194-203.
10. Whiteside TL. Immune suppression in cancer: effects on immune cells, mechanisms and future therapeutic intervention. Semin Cancer Biol. 2006;16:3-15.
11. Lizee G, Radvanyi LG, Overwijk WW, et al. Immunosuppression inmelanoma immunotherapy: potential opportunities for intervention. Clin Cancer Res. 2006;17:2359s-65s.
12. Murali P, Somasundaram R, Chiplunkar S, et al. Monocyte/macrophage functions in patients with squamous cell carcinoma of the oral cavity. J Oral Pathol Med. 1989;18:539-543.
13. del Fresno C, Otero K, Gomez-GarcNa L, et al. Tumor cells deactivate human monocytes by up-regulating IL-1 receptor associated kinase-M expression via CD44 and TLR4. J Immunol. 2005;174:3032-3040.
14. Ugurel S, Uhlig D, Pfohler C, et al. Down-regulation of HLA class II and costimulatory CD86/B7-2 on circulating monocytes from melanoma patients. Cancer Immunol Immunother. 2004;53:551-559.
15. Mytar B, Woloszyn M, Szatanek R, et al. Tumor cell-induced deactivation of human monocytes. J Leukoc Biol. 2003;74:1094-1101.
16. Luczyriski W, Stasiak-Barmuta A, Krawczuk-Rybak M, et al. Monocytes in children with leukemias and lymphomas-down-regulation of HLA and costimulatory molecules. Acta Biochim Pol. 2004;51:1067-1073.
17. Gordon IO, Freedman RS. Defective antitumor function of monocyte-derived macrophages from epithelial ovarian cancer patients. Clin Cancer Res. 2006;12:1515-1524.
18. Benedet JL, Bender H, Jones H, et al. FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. FIGO Committee on Gynecologic Oncology. Int J Gynaecol Obstet. 2000;70:209-262.
19. Gabrilovich D, Corak J, Ciernik I, et al. Decreased antigen presentation by dendritic cells in patients with breast cancer. Clin Cancer Res. 1997;3:483-490.
20. Balkwill F. Cancer and the chemokine network. Nat Rev. 2004;4:540-550.